Skip to content
2020 OptimEyes Technologies Logo

About us

20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, we have successful pre-clinical studies in glaucoma, dry eye and uveitis.

20/20 OptimEyes Technologies is seeking partners to further develop ophthalmic assets or those with novel or repurposed APIs for co-development opportunities in humans and companion animals. The company is also looking for partners with assets targeting other mucosal areas (nasal, optic, buccal, vaginal or GI).

Program engagement

20/20 OptimEyes Technologies

Status

Intellectual Property

Fundraising

Sector

Subsector

The Big DiF Innovation Factory's 15th Annual Open House on May 1 2025 from 4pm - 8pm

Join Innovation Factory's Annual Open House - The Big DiF!

Network with 300+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.

May 1, 2025 | 4:00pm – 8:00pm | Hamilton, Ontario